In HFD mice model, treatment with 134 reduced LXRα and associated target gene product expression, implying the purpose of attenuating NASH as a selective LXRα antagonist (Sim et al., 2014; Zanellaa et al., 2017). Here, NR1H3 is linked to metabolic dysfunction-associated steatohepatitis.